Medical technology firm Ypsomed Group has collaborated with Thin Film Electronics to develop next generation medical injection devices.
Ypsomed plans to invest around CHF50m ($51.2m) in the research and development of new generation of injection and infusion systems to support the administration of medications with intelligent electronic and software-based additional functions.
Thinfilm CEO Davor Sutija said: "Ypsomed is at the forefront of self-medication delivery systems, and it’s clear that a focus on user-friendly products and the patient experience has played a key role in their success."
As part of the deal, Thinfilm will integrate its NFC OpenSense technology in YpsoMate autoinjector to improve patient self-care compliance.
YpsoMate autoinjectors are disposable two-step injection systems, which house pre-filled glass or polymer syringes, and can be operated by push-on-skin activation.
Autoinjectors will be used by patients to self-deliver periodic injections for the ongoing management of chronic conditions such as rheumatoid arthritis or cardiovascular indications.
Patients can receive valuable compliance assistance such as adherence history, injection reminders, usage guidelines, refill instructions and authentication through the combination of the NFC OpenSense tags and a custom mobile app.
NFC OpenSense tags are thin and flexible labels that will detect both the state before and after injection of YpsoMate Smart autoinjector.
The content will be wirelessly delivered to patients through the simple tap of a smartphone, and records patients’ interactions with the YpsoMate Smart device in the cloud.
Image: Thinfilm to integrate NFC OpenSense technology in YpsoMate autoinjector. Photo: courtesy of Business Wire/ Thin Film Electronics ASA.